Since the MV Hondius outbreak, internet searches comparing hantavirus and COVID-19 have surged. The comparison is understandable — both are zoonotic viruses capable of causing severe pneumonia — but the differences matter enormously for how each is managed, prevented, and how concerned the public should actually be.
Origin: Both Come from Animals
Both SARS-CoV-2 (the virus that causes COVID-19) and hantaviruses are zoonotic — they originate in animal reservoirs and have crossed into humans. Both are RNA viruses, meaning their genetic material is RNA rather than DNA, which allows for faster mutation rates.
But the animal sources and evolutionary histories are very different:
COVID-19: SARS-CoV-2 is a coronavirus, most likely originating in bats with a possible intermediate host. Coronaviruses are single-stranded, positive-sense RNA viruses.
Hantavirus: Hantaviruses are rodent-borne, carried specifically by small mammals — primarily mice and voles. They are segmented, negative-sense RNA viruses (Bunyavirales order). Hantaviruses have co-evolved with their rodent hosts over millions of years and are deeply integrated into specific rodent populations worldwide.
Transmission: The Critical Difference
This is where the comparison diverges most significantly.
COVID-19 spreads efficiently person-to-person via respiratory droplets and aerosols. An infected person can transmit the virus to multiple others without any shared environmental exposure. This is what allowed SARS-CoV-2 to cause a global pandemic — sustained community transmission with an effective reproduction number (R₀) of 2–6 in unmitigated populations.
Hantavirus (almost always) requires direct exposure to infected rodent excreta — urine, faeces, or saliva — typically via inhalation of aerosolised particles. There is no person-to-person transmission for any hantavirus strain except Andes virus, and even Andes virus appears to require prolonged close contact rather than casual exposure.
This fundamental difference in transmission means that even a highly lethal hantavirus like Andes virus (35–40% case fatality rate, far higher than COVID-19’s crude fatality rate) cannot generate the exponential community spread that makes respiratory viruses globally dangerous.
Incubation Period
COVID-19: 2–14 days, most commonly 4–6 days.
Hantavirus (HPS): 1–8 weeks, most commonly 2–4 weeks. The long incubation period means that people infected during travel may not develop symptoms until they have returned home, complicating outbreak investigation and contact tracing significantly.
Disease Presentation
Both viruses can cause severe pneumonia, but through different mechanisms:
COVID-19 primarily causes an inflammatory syndrome affecting the lungs, blood vessels, and multiple organ systems. The most severe cases involve hyperinflammation (“cytokine storm”), coagulopathy, and multi-organ failure.
Hantavirus Pulmonary Syndrome (HPS) — the North and South American form — causes massive fluid leakage from capillaries into the lungs (non-cardiogenic pulmonary oedema), leading to respiratory failure within hours of the onset of the cardiopulmonary phase. The shock phase can be so rapid that patients who appeared stable in the morning are in cardiac arrest by the afternoon. This speed of deterioration distinguishes HPS from most other severe respiratory illnesses.
HFRS — the European and Asian form — primarily damages the kidneys rather than the lungs, causing haemorrhagic fever with renal syndrome. Mortality varies widely: Puumala virus (Europe) causes a relatively mild illness with CFR below 1%, while Hantaan virus (Korea, China, Russia) has CFR of 5–15%.
Who Is at Highest Risk?
COVID-19 was notable for its age gradient — severe outcomes were dramatically more common in older adults and those with chronic conditions (cardiovascular disease, diabetes, immunosuppression).
Hantavirus does not show the same age gradient. Historically, HPS cases in North and South America skew toward younger, otherwise healthy adults and adolescents, partly because these groups are more likely to engage in the outdoor and rural activities that produce exposure. The virus does not spare the immunocompetent.
Treatment
COVID-19: Multiple approved antiviral treatments (remdesivir, nirmatrelvir/ritonavir), monoclonal antibodies for high-risk patients, and widespread vaccine coverage provide a substantial therapeutic toolkit.
Hantavirus: No approved antiviral treatment exists. Management is entirely supportive — fluid balance, oxygen, and mechanical ventilation for severe cases. Ribavirin has been studied but evidence for efficacy in HPS is weak. There is no approved hantavirus vaccine in most countries, though candidates are in development. Chile has made progress on a vaccine candidate specific to Andes virus.
Pandemic Potential
COVID-19 demonstrated pandemic potential by sustaining efficient person-to-person transmission globally.
Hantavirus has limited pandemic potential as long as most strains remain dependent on rodent-to-human transmission. Andes virus is the exception — its limited person-to-person capability is a biological outlier that warrants vigilant research. The MV Hondius cluster represents the most complex Andes virus event to date and is being studied closely precisely because of what it might reveal about the virus’s person-to-person transmission potential.
The WHO’s preliminary conclusion from the Hondius investigation — “limited but not conclusive” evidence of person-to-person spread — reflects both the genuine scientific concern and the current limits of the evidence.
Should You Be More Worried About Hantavirus Than COVID?
For most people in most settings: no. The global burden of COVID-19 remains far larger than hantavirus, and the exposure risks are fundamentally different. You don’t need to worry about hantavirus at a shopping centre, on a plane, or in any urban setting. The risk is specific to rodent-contaminated environments in endemic regions.
For travellers to Patagonia, rural North America, or other endemic regions, hantavirus deserves the same awareness that travellers bring to malaria, dengue, or other geographically specific infectious diseases. Know the risk, take targeted precautions, and seek prompt medical evaluation if you develop relevant symptoms after a potential exposure.
See the full symptoms guide and the prevention guide for practical guidance.
Sources
- WHO Hantavirus Fact Sheet
- WHO COVID-19 Dashboard
- CDC Hantavirus
- Mackow ER & Gavrilovskaya IN (2009). Cellular receptors and hantavirus pathogenesis. Current Topics in Microbiology and Immunology.
Explore HantavirusMap